Medications to Manage Pancreatitis on Mounjaro (tirzepatide for T2D): First-Line and Beyond

Published Jul 14, 2025Updated Oct 30, 2026Last reviewed Jul 14, 2025

3 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

What the Mounjaro label says about suspected pancreatitis / Discontinue the drug and begin appropriate management [1]
Symptoms the label flags / Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1]
Pancreatitis risk across nine tirzepatide trials / RR 1.46, 95% CI 0.59 to 3.61, not statistically significant [2]
Pancreatitis risk across 21 GLP-1 receptor agonist trials involving 99,599 patients / No difference from control [3]
Mean lab changes on Mounjaro / Pancreatic amylase up 33% to 38%, lipase up 31% to 42% [1]

What does the Mounjaro label say to do?

The pancreatitis section of the Mounjaro label says that if pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management [1]. The label notes that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists or Mounjaro [1]. It lists persistent or severe abdominal pain, sometimes radiating to the back, as a possible sign; nausea or vomiting may or may not accompany it [1].

What do trials show about pancreatitis risk?

A 2023 meta-analysis pooled nine randomized tirzepatide trials in type 2 diabetes and obesity, 9,871 participants (6,828 on tirzepatide, 3,043 controls), and found no statistically significant increase in pancreatitis (RR 1.46, 95% CI 0.59 to 3.61) [2]. The same analysis found a significant increase in the composite of gallbladder or biliary disease (RR 1.97, 95% CI 1.14 to 3.42) [2]. A 2025 meta-analysis of 21 randomized trials involving 99,599 patients compared GLP-1 receptor agonists, including tirzepatide, with placebo or other controls and found no difference in pancreatitis between groups [3].

In the pooled placebo-controlled adult trials, abdominal pain was reported by 4% of placebo patients and 5% to 6% of tirzepatide patients, nausea by 4% and 12% to 18%, and vomiting by 2% and 5% to 9% [1]. The label reports mean increases from baseline in serum pancreatic amylase of 33% to 38% and in lipase of 31% to 42%, and states that the clinical significance of elevations in lipase or amylase is unknown in the absence of other signs and symptoms of pancreatitis [1]. Acute gallbladder disease was reported in 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients; the label says that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1].

Can Mounjaro be restarted after an episode?

The pancreatitis section of the label instructs discontinuation if pancreatitis is suspected and does not describe restarting the drug after an episode [1].

Frequently asked questions

What does the label say to do if pancreatitis is suspected on Mounjaro?

The label says to discontinue Mounjaro and initiate appropriate management if pancreatitis is suspected [1]. The label lists persistent or severe abdominal pain, sometimes radiating to the back, as a possible sign, with or without nausea or vomiting [1].

Does tirzepatide actually cause pancreatitis?

The label lists acute pancreatitis as a warning and says cases, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, have been observed with GLP-1 receptor agonists or Mounjaro [1]. Pooled trial data have not shown a statistically significant increase (RR 1.46, 95% CI 0.59 to 3.61) [2], and a 2025 meta-analysis of 21 trials involving 99,599 patients found no difference in pancreatitis between GLP-1 receptor agonists and controls [3].

Is a high lipase on Mounjaro proof of pancreatitis?

The label reports mean increases from baseline of 33% to 38% in serum pancreatic amylase and 31% to 42% in lipase, and states that the clinical significance of elevations in lipase or amylase is unknown in the absence of other signs and symptoms of pancreatitis [1].

Can Mounjaro be restarted after pancreatitis?